Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Fostemsavir Tris (BMS-663068 Tris) 是一种 HIV-1附着抑制剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 678 | 现货 | ||
2 mg | ¥ 987 | 现货 | ||
5 mg | ¥ 1,730 | 现货 | ||
10 mg | ¥ 2,590 | 现货 | ||
25 mg | ¥ 4,330 | 现货 | ||
50 mg | ¥ 6,120 | 现货 | ||
100 mg | ¥ 8,260 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,680 | 现货 |
产品描述 | Fostemsavir Tris (BMS-663068 Tris) is the prodrug of BMS-626529,is a oral, safe and effective inhibitor of HIV-1 attachment. It inhibits human immunodeficiency virus type 1 (HIV-1) infection by binding to gp120 and interfering with the attachment of virus to CD4+ T-cells. |
体内活性 |
BMS-663068 is the phosphonooxymethyl prodrug of BMS-626529, a novel small-molecule attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4(+) T cells.The activity of BMS-626529 is virus dependent, due to heterogeneity within gp120.?BMS-626529 had half-maximal effective concentration (EC(50)) values of <10 nM against the vast majority of viral isolates;?however, susceptibility varied by >6 log(10), with half-maximal effective concentration values in the low pM range against the most susceptible viruses.?The in vitro antiviral activity of BMS-626529 was generally not associated with either tropism or subtype, with few exceptions.?Measurement of the binding affinity of BMS-626529 for purified gp120 suggests that a contributory factor to its inhibitory potency may be a relatively long dissociative half-life.? |
别名 | BMS-663068 Tris |
分子量 | 704.62 |
分子式 | C29H37N8O11P |
CAS No. | 864953-39-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (177.40 mM), sonification is recommended.
H2O: 100 mg/mL (141.92 mM), sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / H2O | 1 mM | 1.4192 mL | 7.096 mL | 14.192 mL | 35.4801 mL |
5 mM | 0.2838 mL | 1.4192 mL | 2.8384 mL | 7.096 mL | |
10 mM | 0.1419 mL | 0.7096 mL | 1.4192 mL | 3.548 mL | |
20 mM | 0.071 mL | 0.3548 mL | 0.7096 mL | 1.774 mL | |
50 mM | 0.0284 mL | 0.1419 mL | 0.2838 mL | 0.7096 mL | |
100 mM | 0.0142 mL | 0.071 mL | 0.1419 mL | 0.3548 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Fostemsavir Tris 864953-39-9 Microbiology/Virology Proteases/Proteasome HIV Protease Inhibitor BMS-663068 Tris inhibit BMS 663068 BMS663068 HIV Human immunodeficiency virus Fostemsavir BMS-663068 inhibitor